R&G PharmaStudies Co., Ltd. (SHE:301333)

China · Delayed Price · Currency is CNY

52.99

+1.85 (3.62%)

Jul 14, 2026, 4:00 PM EDT

1.53% (1Y)

Market Cap	5.09B +7.6%
Revenue (ttm)	896.26M +21.2%
Net Income	133.65M -6.7%
EPS	1.40 -6.5%
Shares Out	95.99M
PE Ratio	37.81
Forward PE	30.63
Dividend	0.16 (0.31%)
Ex-Dividend Date	Jul 3, 2026

Volume	3,918,820
Open	50.63
Previous Close	51.14
Day's Range	49.52 - 53.11
52-Week Range	43.79 - 91.78
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquarter... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2008

Employees 2,645

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301333

Full Company Profile

Financial Performance

In 2025, R&G PharmaStudies's revenue was 851.01 million, an increase of 14.38% compared to the previous year's 744.00 million. Earnings were 136.90 million, a decrease of -2.37%.

Financial Statements